The victims or deceased names are not mentioned in the given text. : “Indian Cough Syrup Linked to Child Deaths Found with Quality Issues: Sources”

Death – Obituary – Accident and Crime News : Indian Cough Syrup Linked to Child Deaths Found to Have Quality Issues in Tests

BHOPAL, India – Tests conducted on a cough syrup linked to the deaths of at least six children in Cameroon have revealed unidentified quality issues in at least one of the five samples collected by authorities, according to sources familiar with the investigation.

Riemann Labs, one of three Indian drugmakers whose cough syrups have been linked to the deaths of 141 children in Gambia, Uzbekistan, and Cameroon since last year, has raised concerns about the quality of Indian exports. India is known as the “world’s pharmacy” for its supply of low-cost life-saving drugs to countries in need.

In July, the World Health Organization (WHO) reported that a sample of Naturcold syrup from Cameroon, identified as Riemann’s product, contained 28.6% diethylene glycol toxin, exceeding the acceptable limit of 0.10%.

Following the WHO alert, Indian authorities suspended Riemann’s production due to violations of good manufacturing practices. Five samples of Naturcold syrup were sent for testing, and one of them was found to be of “not standard” quality. The specific issues with the sample were not disclosed until the company had a chance to respond to the notice.

Riemann Labs and the drug regulator of Madhya Pradesh state, where the company is located, have not responded to Reuters’ queries.

During an inspection in June, state and federal regulators found violations at Riemann’s factory, including improper ventilation that increased the risk of cross-contamination.

Riemann reportedly informed the state regulator that it was conducting repairs to resume production. Other Indian cough syrup manufacturers linked to the overseas deaths have also applied to reopen their factories.

Since June, India has made tests mandatory for cough syrup exports and has increased scrutiny of drugmakers, uncovering various deficiencies, such as poor documentation and a lack of self-assessment, during recent inspections.

The investigation into the quality issues of the cough syrup samples continues. The Indian authorities are committed to ensuring the safety and efficacy of pharmaceutical products, especially those intended for export.

Leave a Comment